Yong Mee Cho
Overview
Explore the profile of Yong Mee Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1097
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sung J, Lee Y, Kim Y, Song C, Park J, Yoon S, et al.
BJU Int
. 2024 Nov;
135(3):510-516.
PMID: 39587415
Objectives: To investigate the impact of the revised papillary renal cell carcinoma (PRCC) classification and evaluate its validity with regard to oncological outcome stratification. Patients And Methods: Identifying 527 patients...
2.
Park J, Shin S, Kim H, Oh S, Cho Y
J Pathol Transl Med
. 2024 Sep;
58(6):321-330.
PMID: 39257049
Background: Papillary renal cell carcinoma (pRCC) is the second most common histological subtype of renal cell carcinoma and is considered a morphologically and molecularly heterogeneous tumor. Accurate classification and assessment...
3.
Jeong J, Kim D, Ryu Y, Park J, Yoon S, Ahn B, et al.
J Pathol Transl Med
. 2024 Aug;
58(5):229-240.
PMID: 39112099
Background: Bladder cancer is characterized by frequent mutations, which provide potential therapeutic targets for most patients. The effectiveness of emerging personalized therapies depends on an accurate molecular diagnosis, for which...
4.
Kim M, Shim H, Kim S, Lee I, Kim J, Yoon S, et al.
J Pathol Transl Med
. 2024 Jul;
58(4):147-164.
PMID: 39026440
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope...
5.
Park I, Suh J, Lim B, Song C, You D, Jeong I, et al.
Clin Genitourin Cancer
. 2024 Apr;
22(3):102069.
PMID: 38580522
Purpose: The study aimed to investigate the impact of adjuvant chemotherapy on time to recurrence (TTR) and overall survival (OS) in patients with histologic variants of upper tract urothelial carcinoma...
6.
Jeong S, Park J, Yoon S, Hwang H, Go H, Shin D, et al.
Investig Clin Urol
. 2024 Jan;
65(1):84-93.
PMID: 38197755
Purpose: Vascular endothelial growth factor tyrosine kinase inhibitors (TKIs) have been the standard of care for advanced and metastatic clear cell renal cell carcinoma (ccRCC). However, the therapeutic effect of...
7.
Ahn B, Kim D, Park K, Park J, Yoon S, Hong B, et al.
Cancer Res Treat
. 2023 Dec;
56(3):856-870.
PMID: 38147818
Purpose: In this study, we aimed to determine the clinicopathologic, radiologic, and molecular significance of the tumor invasiveness to further stratify the patients with high-grade (HG) upper tract urothelial carcinoma...
8.
Hyung J, Kim H, Kim G, Cho Y, Ryu Y, Kim S, et al.
Cancer Res Treat
. 2023 Dec;
56(2):624-633.
PMID: 38037320
Purpose: Small cell carcinoma of the genitourinary tract (GU SCC) is a rare disease with a poor prognosis. There are only limited treatment options due to insufficient understanding of the...
9.
Kim M, Shim H, Kim S, Lee I, Kim J, Yoon S, et al.
Cancer Res Treat
. 2023 Dec;
56(3):721-742.
PMID: 38037319
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope...
10.
Kim Y, Ju H, Yoo S, Jeong J, Heo J, Lee S, et al.
Cell Rep Med
. 2023 Oct;
4(10):101224.
PMID: 37797616
Radical cystectomy with preoperative cisplatin-based neoadjuvant chemotherapy (NAC) is the standard care for muscle-invasive bladder cancers (MIBCs). However, the complete response rate to this modality remains relatively low, and current...